Carbonic anhydrases: novel therapeutic applications for inhibitors and activators

Carbonic anhydrases (CAs), a group of ubiquitously expressed metalloenzymes, are involved in numerous physiological and pathological processes, including gluconeogenesis, lipogenesis, ureagenesis, tumorigenicity and the growth and virulence of various pathogens. In addition to the established role of CA inhibitors (CAIs) as diuretics and antiglaucoma drugs, it has recently emerged that CAIs could have potential as novel anti-obesity, anticancer and anti-infective drugs. Furthermore, recent studies suggest that CA activation may provide a novel therapy for Alzheimer's disease. This article discusses the biological rationale for the novel uses of inhibitors or activators of CA activity in multiple diseases, and highlights progress in the development of specific modulators of the relevant CA isoforms, some of which are now being evaluated in clinical trials.

[1]  C. Supuran,et al.  Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. , 2005, Journal of medicinal chemistry.

[2]  C. Steegborn,et al.  Cryptococcus neoformans Senses CO2 through the Carbonic Anhydrase Can2 and the Adenylyl Cyclase Cac1 , 2006, Eukaryotic Cell.

[3]  Andrea Scozzafava,et al.  Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives. , 2003, Journal of medicinal chemistry.

[4]  C. Supuran,et al.  Carbonic anhydrase inhibitors: sulfonamides incorporating furan-, thiophene- and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions. , 2000, Bioorganic & medicinal chemistry.

[5]  C. Supuran,et al.  Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors. , 2006, Bioorganic & medicinal chemistry letters.

[6]  C. Supuran,et al.  Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs. , 2006, Journal of medicinal chemistry.

[7]  A. Bird,et al.  Treatment of chronic macular edema with acetazolamide. , 1988, Archives of ophthalmology.

[8]  Alessio Innocenti,et al.  Antiviral sulfonamide derivatives. , 2004, Mini reviews in medicinal chemistry.

[9]  J. Pronk,et al.  Carbonic anhydrase (Nce103p): an essential biosynthetic enzyme for growth of Saccharomyces cerevisiae at atmospheric carbon dioxide pressure. , 2005, The Biochemical journal.

[10]  C. Supuran,et al.  Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. , 2005, Bioorganic & medicinal chemistry letters.

[11]  C. Supuran,et al.  Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. , 2006, Journal of medicinal chemistry.

[12]  Fungal Adenylyl Cyclase Integrates CO2 Sensing with cAMP Signaling and Virulence , 2005, Current Biology.

[13]  C. Supuran,et al.  Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. , 2003, Bioorganic & medicinal chemistry letters.

[14]  W. Sly,et al.  Localization of Carbonic Anhydrase XII to the Basolateral Membrane of H+-secreting Cells of Mouse and Rat Kidney , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[15]  C. Supuran,et al.  Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. , 2005, Bioorganic & medicinal chemistry letters.

[16]  B. Read,et al.  Identification and Preliminary Characterization of Two cDNAs Encoding Unique Carbonic Anhydrases from the Marine Alga Emiliania huxleyi , 2006, Applied and Environmental Microbiology.

[17]  C. Supuran,et al.  Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library. , 2004, Journal of medicinal chemistry.

[18]  Andrea Scozzafava,et al.  Carbonic anhydrase inhibitors. , 2001, Medicinal research reviews.

[19]  C. Supuran,et al.  Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides. , 2004, Bioorganic & medicinal chemistry letters.

[20]  M. F. Sugrue.  Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors , 2000, Progress in Retinal and Eye Research.

[21]  T. Owa,et al.  Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. , 1999, Journal of medicinal chemistry.

[22]  C. Supuran,et al.  Carbonic anhydrase inhibitors. Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with boron-containing sulfonamides, sulfamides, and sulfamates: toward agents for boron neutron capture therapy of hypoxic tumors. , 2005, Bioorganic & medicinal chemistry letters.

[23]  C. Supuran,et al.  Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. , 2004, Journal of medicinal chemistry.

[24]  C. Supuran,et al.  Carbonic anhydrase activators: design of high affinity isozymes I, II, and IV activators, incorporating tri-/tetrasubstituted-pyridinium-azole moieties. , 2002, Journal of medicinal chemistry.

[25]  Donna Richardson,et al.  Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. Supuran,et al.  Inhibition of the Archaeal -Class (Cab) and ?-Class (Cam) Carbonic Anhydrases , 2007 .

[27]  A. Harris,et al.  Hypoxia-Inducible Factor 1α Expression as an Intrinsic Marker of Hypoxia , 2004, Clinical Cancer Research.

[28]  D. Rea,et al.  Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer , 2007, British Journal of Cancer.

[29]  C. Supuran,et al.  Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. , 2004, Bioorganic & medicinal chemistry letters.

[30]  G. Klebe,et al.  Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic aftertaste. , 2007, Angewandte Chemie.

[31]  Richard D. Vaughan-Jones,et al.  Regulation of tumor pH and the role of carbonic anhydrase 9 , 2007, Cancer and Metastasis Reviews.

[32]  J. Pastorek,et al.  Role of Carbonic Anhydrases in the Progression of Renal Cell Carcinoma Subtypes: Proposal of a Unified Hypothesis , 2006, Cancer investigation.

[33]  C. Supuran,et al.  Hypoxia activates the capacity of tumor‐associated carbonic anhydrase IX to acidify extracellular pH , 2004, FEBS letters.

[34]  C. Supuran,et al.  Carbonic anhydrase activators: activation of isozyme XIII with amino acids and amines. , 2006, Bioorganic & medicinal chemistry letters.

[35]  C. Supuran,et al.  Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. , 2006, Journal of medicinal chemistry.

[36]  C. Supuran,et al.  Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. , 2007, Bioorganic & medicinal chemistry.

[37]  P. Ellis,et al.  A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.

[38]  D. Alkon,et al.  Pharmacological enhancement of synaptic efficacy, spatial learning, and memory through carbonic anhydrase activation in rats. , 2001, The Journal of pharmacology and experimental therapeutics.

[39]  C. Supuran,et al.  Activation of carbonic anhydrase isozymes. , 2000, EXS.

[40]  Brendan L Wilkinson,et al.  Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides. , 2007, Journal of medicinal chemistry.

[41]  C. Supuran,et al.  Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. , 2004, Bioorganic & medicinal chemistry letters.

[42]  J. Heitman,et al.  Carbonic Anhydrase and CO2 Sensing during Cryptococcus neoformans Growth, Differentiation, and Virulence , 2005, Current Biology.

[43]  A. Harris,et al.  Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer , 2003, British Journal of Cancer.

[44]  C. Supuran,et al.  Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. , 2005, Bioorganic & medicinal chemistry letters.

[45]  C. Supuran,et al.  Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. , 2003, Journal of medicinal chemistry.

[46]  C. Supuran,et al.  Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib. , 2006, Bioorganic & medicinal chemistry letters.

[47]  Y. Edwards,et al.  The carbonic anhydrases : new horizons , 2000 .

[48]  Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. , 2004, Bioorganic & medicinal chemistry letters.

[49]  C. Supuran,et al.  Carbonic anhydrase inhibitors and activators and their use in therapy , 2006 .

[50]  T. Thamboo,et al.  An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer. , 2007, The Journal of urology.

[51]  C. Supuran,et al.  Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[52]  Brendan L Wilkinson,et al.  A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing". , 2006, Journal of medicinal chemistry.

[53]  C. Supuran,et al.  Carbonic anhydrase activators: the first activation study of the human secretory isoform VI with amino acids and amines. , 2007, Bioorganic & medicinal chemistry.

[54]  Stephanie J. Fonda,et al.  Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation , 2007, Nature Medicine.

[55]  Alessio Innocenti,et al.  Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. , 2005, Bioorganic & medicinal chemistry letters.

[56]  Luca Menabuoni,et al.  Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties. , 2002, Journal of medicinal chemistry.

[57]  C. Supuran,et al.  Carbonic Anhydrase Inhibitors: Synthesis of Sulfonamides Incorporating 2, 4, 6–Trisubstituted-Pyridinium-Ethylcarboxamido Moieties Possessing Membrane-Impermeability and in Vivo Selectivity for the Membrane-Bound (CA IV) Versus the Cytosolic (CA I and CA II) Isozymes , 2000, Journal of enzyme inhibition.

[58]  C. Supuran,et al.  Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. , 2006, Journal of medicinal chemistry.

[59]  J. Voipio,et al.  Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. , 2005, Bioorganic & medicinal chemistry letters.

[60]  C. Supuran,et al.  Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered. , 2004, Bioorganic & medicinal chemistry letters.

[61]  J. Ferry,et al.  Prokaryotic carbonic anhydrases. , 2000, FEMS microbiology reviews.

[62]  C. Supuran,et al.  Carbonic anhydrase inhibitors — Part 29 1: Interaction of isozymes I, II and IV with benzolamide-like derivatives , 1998 .

[63]  C. Supuran,et al.  Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II , 2006 .

[64]  C. Supuran,et al.  Targeting tumor-associated carbonic anhydrase IX in cancer therapy. , 2006, Trends in pharmacological sciences.

[65]  C. Supuran,et al.  Carbonic anhydrase inhibitors: inhibition of transmembrane, tumor-associated isozyme IX, and cytosolic isozymes I and II with aliphatic sulfamates. , 2003, Journal of medicinal chemistry.

[66]  K. Gadde,et al.  Zonisamide for weight loss in obese adults: a randomized controlled trial. , 2003, JAMA.

[67]  S. Krungkrai,et al.  Carbonic anhydrase inhibitors. Inhibition of Plasmodium falciparum carbonic anhydrase with aromatic sulfonamides: towards antimalarials with a novel mechanism of action? , 2005, Bioorganic & medicinal chemistry.

[68]  C. Supuran,et al.  Carbonic anhydrase activators: amino acyl/dipeptidyl histamine derivatives bind with high affinity to isozymes I, II and IV and act as efficient activators. , 1999, Bioorganic & medicinal chemistry.

[69]  A. Harris,et al.  Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. , 2007, Cancer letters.

[70]  C. Supuran,et al.  Carbonic anhydrase activators: human isozyme II is strongly activated by oligopeptides incorporating the carboxyterminal sequence of the bicarbonate anion exchanger AE1. , 2002, Bioorganic & medicinal chemistry letters.

[71]  T. Owa,et al.  Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide. , 2002, Journal of medicinal chemistry.

[72]  D. Alkon,et al.  Carbonic anhydrase gating of attention: memory therapy and enhancement. , 2002, Trends in pharmacological sciences.

[73]  C. Supuran,et al.  Carbonic anhydrase inhibitors: synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes. , 2000, Journal of medicinal chemistry.

[74]  Y. Deshaies,et al.  Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. , 2000, Obesity research.

[75]  C. Supuran,et al.  Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. , 2004, Journal of enzyme inhibition and medicinal chemistry.

[76]  C. Supuran,et al.  Carbonic Anhydrase: Its Inhibitors and Activators , 2007 .

[77]  C. Supuran,et al.  Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action. , 2000, Journal of medicinal chemistry.

[78]  T. Owa,et al.  Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. , 2004, Bioorganic & medicinal chemistry letters.

[79]  C. Supuran,et al.  Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties. , 2005, Journal of medicinal chemistry.

[80]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[81]  C. Supuran,et al.  Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV. , 2007, Bioorganic & medicinal chemistry letters.

[82]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[83]  Christopher J. Schofield,et al.  Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL , 2002, Nature.

[84]  C. Supuran,et al.  Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors. , 2005, Journal of medicinal chemistry.

[85]  C. Supuran,et al.  Membrane-bound carbonic anhydrases in osteoclasts. , 2007, Bone.

[86]  J. Pouysségur,et al.  Hypoxia and cancer , 2007, Journal of Molecular Medicine.

[87]  C. Supuran,et al.  Carbonic anhydrase activators: the first X-ray crystallographic study of an adduct of isoform I. , 2006, Bioorganic & medicinal chemistry letters.

[88]  T. Bergfors,et al.  Structure and Function of Carbonic Anhydrases from Mycobacterium tuberculosis* , 2005, Journal of Biological Chemistry.

[89]  C. Supuran,et al.  Carbonic anhydrase activators. 3: structure-activity correlations for a series of isozyme II activators. , 1994, Journal of pharmaceutical sciences.

[90]  W. Sly,et al.  Characterization of CA XIII, a Novel Member of the Carbonic Anhydrase Isozyme Family* , 2004, Journal of Biological Chemistry.

[91]  C. Supuran,et al.  Carbonic anhydrase activators: high affinity isozymes I, II, and IV activators, incorporating a beta-alanyl-histidine scaffold. , 2002, Journal of medicinal chemistry.

[92]  C. Supuran,et al.  Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? , 1999, Journal of medicinal chemistry.

[93]  C. Supuran,et al.  Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. , 2004, Bioorganic & medicinal chemistry letters.

[94]  Andrea Scozzafava,et al.  Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors. , 2007, Journal of medicinal chemistry.

[95]  C. Supuran.  Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity , 2003 .

[96]  C. Supuran,et al.  Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII, and XIV with l- and d-histidine and crystallographic analysis of their adducts with isoform II: engineering proton-transfer processes within the active site of an enzyme. , 2006, Chemistry.

[97]  C. Supuran,et al.  COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. , 2004, Mini reviews in medicinal chemistry.

[98]  C. Supuran,et al.  Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route. , 1999, Journal of medicinal chemistry.

[99]  C. Supuran,et al.  The development of topically acting carbonic anhydrase inhibitors as anti-glaucoma agents. , 2007, Current topics in medicinal chemistry.

[100]  T. Maren,et al.  The Development of Topical Carbonic Anhydrase Inhibitors , 1995, Journal of glaucoma.

[101]  C. Supuran,et al.  Carbonic anhydrase inhibitors. Inhibition of the beta-class enzyme from the methanoarchaeon Methanobacterium thermoautotrophicum (Cab) with anions. , 2004, Bioorganic & medicinal chemistry letters.

[102]  C. Supuran,et al.  Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride. , 2004, Bioorganic & medicinal chemistry letters.

[103]  J. Pouysségur,et al.  Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.

[104]  P. Ratcliffe,et al.  Targeting tumors through the HIF system , 2000, Nature Medicine.

[105]  Emmanuel Chamorey,et al.  HIF‐1α and CA IX staining in invasive breast carcinomas: Prognosis and treatment outcome , 2007 .

[106]  C. Supuran,et al.  Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs? , 2005, Bioorganic & medicinal chemistry letters.

[107]  J. Pouysségur,et al.  Oxygen, a source of life and stress , 2007, FEBS letters.

[108]  C. Supuran,et al.  Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide. , 2004, Bioorganic & medicinal chemistry letters.

[109]  Andrea Scozzafava,et al.  Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II. , 2005, Journal of medicinal chemistry.

[110]  D. Christianson,et al.  X-ray crystallographic studies of mammalian carbonic anhydrase isozymes. , 2000, EXS.

[111]  P. Lambin,et al.  Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[112]  S Mangani,et al.  Carbonic anhydrase activators: X-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine. , 1997, Biochemistry.

[113]  M. Lerman,et al.  Expression of cell surface transmembrane carbonic anhydrase genes CA9 and CA12 in the human eye: overexpression of CA12 (CAXII) in glaucoma , 2003, Journal of medical genetics.

[114]  C. Supuran,et al.  Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX. , 2006, Journal of the American Chemical Society.

[115]  C. Supuran,et al.  Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. , 2003, Bioorganic & medicinal chemistry letters.

[116]  C. Supuran,et al.  Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxysulfamides--a new zinc-binding function in the design of inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[117]  A. Harris,et al.  Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer. , 2004, International journal of radiation oncology, biology, physics.